Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
University of Nebraska
National Cancer Institute (NCI)
Fundación de investigación HM
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
Cellectar Biosciences, Inc.
Centre Oscar Lambret
M.D. Anderson Cancer Center
Endeavor Biomedicines, Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company
Servier
Jazz Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
Turning Point Therapeutics, Inc.
City of Hope Medical Center
Stanford University
Milton S. Hershey Medical Center
Novartis
University of Alabama at Birmingham
Mayo Clinic
Thomas Jefferson University
Institut du Cancer de Montpellier - Val d'Aurelle
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Blueprint Medicines Corporation
Northwell Health
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Lumos Pharma
Washington University School of Medicine
University of Alabama at Birmingham
Deciphera Pharmaceuticals, LLC
Eisai Inc.